STREPSILS INTENSIVE spray external. 8.75 mg/dose vial. 15 ml

STREPSILS INTENSIVE spray external. 8.75 mg/dose vial. 15 ml

Interaction

The simultaneous use of the drug with the following drugs should be avoided:
- Acetylsalicylic acid: with the exception of low doses of acetylsalicylic acid (no more than 75 mg per day) prescribed by a doctor, since combined use may increase the risk of side effects.

- Other NSAIDs, including ibuprofen and selective cyclooxygenase-2 inhibitors: The simultaneous use of two or more NSAIDs should be avoided due to a possible increased risk of side effects.

Use with caution simultaneously with the following medications:

- Anticoagulants: NSAIDs may enhance the effects of anticoagulants, including warfarin.

- Antiplatelet agents and selective serotonin reuptake inhibitors: increased risk of gastrointestinal bleeding.

- Antihypertensives (ACE inhibitors and angiotensin II antagonists) and diuretics: NSAIDs may reduce the effectiveness of these drugs and may increase nephrotoxicity due to inhibition of cyclooxygenase, especially in patients with impaired renal function (it is necessary to ensure adequate fluid replacement in such patients).

— Ethanol: may increase the risk of adverse reactions, especially gastrointestinal bleeding.

- Cardiac glycosides: simultaneous use of NSAIDs and cardiac glycosides can lead to worsening heart failure, a decrease in glomerular filtration rate and an increase in the concentration of cardiac glycosides in the blood plasma.

— Cyclosporine: increased risk of nephrotoxicity.

- Glucocorticosteroids: increased risk of gastrointestinal ulcers and gastrointestinal bleeding.

— Lithium preparations: there is evidence of the likelihood of an increase in the concentration of lithium in the blood plasma during the use of NSAIDs.

- Methotrexate: there is evidence of the likelihood of an increase in the concentration of methotrexate in the blood plasma during the use of NSAIDs. It is necessary to take NSAIDs 24 hours before or after taking methotrexate.

- Mifepristone: NSAIDs should be started no earlier than 8-12 days after stopping mifepristone, since NSAIDs may reduce the effectiveness of mifepristone.

- Quinolone antibiotics: in patients receiving concomitant treatment with NSAIDs and quinolone antibiotics, the risk of seizures may increase.

- Tacrolimus: when used together with NSAIDs, there may be an increased risk of nephrotoxicity.

- Zidovudine: when used together with NSAIDs, there may be an increased risk of hematotoxicity.

- Oral hypoglycemic drugs: changes in blood glucose concentrations are possible (it is recommended to increase the frequency of monitoring blood glucose concentrations).

- Phenytoin: an increase in the concentration of phenytoin in the blood serum is possible (monitoring the concentration of phenytoin in the blood serum and, if necessary, dose adjustment is recommended).

- Potassium-sparing diuretics: Concomitant use of potassium-sparing diuretics and flurbiprofen may lead to hyperkalemia.

- Probenecid and sulfinpyrazone: Medicines containing probenecid or sulfinpyrazone may delay the elimination of flurbiprofen.

- Tolbutamide and antacids: To date, studies have not identified interactions between flurbiprofen and tolbutamide or antacids.

Strepsils Intensive Spray, 15 ml, 8.75 mg/dose, for topical use

Interaction with other drugs

The simultaneous use of the drug with the following drugs should be avoided: • Acetylsalicylic acid: with the exception of low doses of acetylsalicylic acid (no more than 75 mg per day) prescribed by a doctor, since combined use may increase the risk of side effects. • Other NSAIDs, including ibuprofen and selective cyclooxygenase-2 inhibitors: Concomitant use of two or more NSAIDs should be avoided due to a possible increased risk of side effects. Use with caution simultaneously with the following drugs: • Anticoagulants: NSAIDs may enhance the effects of anticoagulants, including warfarin. • Antiplatelet agents and selective serotonin reuptake inhibitors: increased risk of gastrointestinal bleeding. • Antihypertensives (ACE inhibitors and angiotensin II antagonists) and diuretics: NSAIDs may reduce the effectiveness of these drugs and may increase nephrotoxicity due to cyclooxygenase inhibition, especially in patients with impaired renal function (it is necessary to ensure adequate fluid replacement in such patients). • Ethanol: may increase the risk of adverse reactions, especially gastrointestinal bleeding. • Cardiac glycosides: simultaneous use of NSAIDs and cardiac glycosides can lead to worsening heart failure, a decrease in glomerular filtration rate and an increase in the concentration of cardiac glycosides in the blood plasma. • Cyclosporine: increased risk of nephrotoxicity. • Glucocorticosteroids: increased risk of gastrointestinal ulceration and gastrointestinal bleeding. • Lithium preparations: there is evidence of the likelihood of an increase in the concentration of lithium in the blood plasma during the use of NSAIDs. • Methotrexate: there is evidence of the likelihood of an increase in the concentration of methotrexate in the blood plasma during the use of NSAIDs. It is necessary to take NSAIDs 24 hours before or after taking methotrexate. • Mifepristone: NSAIDs should be started no earlier than 8-12 days after stopping mifepristone, as NSAIDs may reduce the effectiveness of mifepristone. • Quinolone antibiotics: Patients receiving concomitant treatment with NSAIDs and quinolone antibiotics may have an increased risk of seizures. • Tacrolimus: when used together with NSAIDs, there may be an increased risk of nephrotoxicity. • Zidovudine: when used together with NSAIDs, there may be an increased risk of hematotoxicity. m • Oral hypoglycemic drugs: possible changes in blood glucose concentrations (it is recommended to increase the frequency of monitoring blood glucose concentrations). • Phenytoin: an increase in the concentration of phenytoin in the blood serum is possible (monitoring the concentration of phenytoin in the blood serum and, if necessary, dose adjustment is recommended). • Potassium-sparing diuretics: Concomitant use of potassium-sparing diuretics and flurbiprofen may lead to hyperkalemia. • Probenecid and sulfinpyrazone: Medicines containing probenecid or sulfinpyrazone may delay the elimination of flurbiprofen. • Tolbutamide and antacids: To date, studies have shown no interactions between flurbiprofen and tolbutamide or antacids.

Strepsils Intensive spray dosage for places approx 8.75 mg/dose 15 ml (fl)

The simultaneous use of the drug with the following drugs should be avoided: • Acetylsalicylic acid: with the exception of low doses of acetylsalicylic acid (no more than 75 mg per day) prescribed by a doctor, since combined use may increase the risk of side effects. • Other NSAIDs, including ibuprofen and selective cyclooxygenase-2 inhibitors: Concomitant use of two or more NSAIDs should be avoided due to a possible increased risk of side effects.

Use with caution simultaneously with the following drugs: • Anticoagulants: NSAIDs may enhance the effects of anticoagulants, including warfarin.

• Antiplatelet agents and selective serotonin reuptake inhibitors: increased risk of gastrointestinal bleeding.

• Antihypertensives (ACE inhibitors and angiotensin II antagonists) and diuretics: NSAIDs may reduce the effectiveness of these drugs and may increase nephrotoxicity due to cyclooxygenase inhibition, especially in patients with impaired renal function (it is necessary to ensure adequate fluid replacement in such patients).

• Ethanol: may increase the risk of adverse reactions, especially gastrointestinal bleeding.

• Cardiac glycosides: simultaneous use of NSAIDs and cardiac glycosides can lead to worsening heart failure, a decrease in glomerular filtration rate and an increase in the concentration of cardiac glycosides in the blood plasma.

• Cyclosporine: increased risk of nephrotoxicity.

• Glucocorticosteroids: increased risk of gastrointestinal ulceration and gastrointestinal bleeding.

• Lithium preparations: there is evidence of the likelihood of an increase in the concentration of lithium in the blood plasma during the use of NSAIDs.

• Methotrexate: there is evidence of the likelihood of an increase in the concentration of methotrexate in the blood plasma during the use of NSAIDs. It is necessary to take NSAIDs 24 hours before or after taking methotrexate.

• Mifepristone: NSAIDs should be started no earlier than 8-12 days after stopping mifepristone, as NSAIDs may reduce the effectiveness of mifepristone.

• Quinolone antibiotics: Patients receiving concomitant treatment with NSAIDs and quinolone antibiotics may have an increased risk of seizures.

• Tacrolimus: when used together with NSAIDs, there may be an increased risk of nephrotoxicity.

• Zidovudine: when used in combination with NSAIDs, there may be an increased risk of hematotoxicity.

• Oral hypoglycemic drugs: changes in blood glucose concentrations are possible (it is recommended to increase the frequency of monitoring blood glucose concentrations).

• Phenytoin: an increase in the concentration of phenytoin in the blood serum is possible (monitoring the concentration of phenytoin in the blood serum and, if necessary, dose adjustment is recommended).

• Potassium-sparing diuretics: Concomitant use of potassium-sparing diuretics and flurbiprofen may lead to hyperkalemia.

• Probenecid and sulfinpyrazone: Medicines containing probenecid or sulfinpyrazone may delay the elimination of flurbiprofen.

• Tolbutamide and antacids: To date, studies have shown no interactions between flurbiprofen and tolbutamide or antacids.

Strepsils intensive

Strepsils Intensive (flurbiprofen) is an NSAID in the form of lozenges for use in otorhinolaryngological and dental practice. Shows a pronounced analgesic, anti-inflammatory and antipyretic effect. Inhibits the enzyme COX types 1 and 2 (mostly COX-1), which leads to a decrease in the formation of nociceptive, hyperthermic and pro-inflammatory mediators of prostaglandins. Anesthetizes and relieves inflammation of the mucous membrane of the oral cavity and oropharynx, prevents excess accumulation of fluid in the mucous membrane, facilitates swallowing, and eliminates pain and discomfort in the throat. The drug begins to act within two minutes after administration. In terms of pain intensity, the effect becomes more pronounced after the 20th minute. The peak effect of the drug is observed after 1-1.5 hours. The duration of action of the drug is up to four hours. The time for complete dissolution of the tablet in the oral cavity takes from 5 to 12 minutes. The active substance has a high degree of absorption and enters the bloodstream after just five minutes. Peak concentration in the blood is reached after 40–45 minutes. In the liver it undergoes metabolic transformations by introducing a hydroxyl group into the molecule. Elimination from the body occurs mainly through urine and to a small extent through bile, with approximately a quarter of the administered dose being excreted unchanged. The half-life varies from 3 to 6 hours. Strepsils Intensive is indicated for the symptomatic treatment of ENT infections accompanied by pain in the mouth and pharynx. Single dose – 1 tablet. Frequency of use: every 3-6 hours, so that no more than 5 tablets are taken per day. Strepsils Intensive is indicated for short-term use only. The maximum duration of the medication course is 3 days. If after this time signs of the disease persist or become more severe, treatment should be interrupted and medical advice should be sought.

The likelihood of developing unwanted side effects can be minimized if you take the drug for a short time and do not exceed the recommended dosage. Typical side effects when taking Strepsils Intensive: headache, dizziness, spontaneously occurring sensations of burning, tingling, crawling, irritation in the throat, diarrhea, ulcerative lesions of the oral mucosa, discomfort in the oral cavity. Strepsils Intensive is not used for hypersensitization of the body and frequent development of local immune (allergic) reactions in response to aspirin or other NSAIDs, manifested by bronchospasm, nasal congestion and rhinorrhea, angioedema, urticaria, nasal polyposis or polyposis of the paranasal sinuses, ulcerative-erosive lesions of the gastrointestinal tract, acute ulcer bleeding, hemophilia, severe liver and kidney diseases, laboratory-diagnosed hypokalemia, as well as in the third trimester of pregnancy. In pediatric practice, the drug is used starting from the age of 12. The drug contains sugar as an auxiliary component, which must be taken into account by people suffering from diabetes. If symptoms of damage to the mucous membrane of the gastrointestinal tract occur, it is necessary to organize strict monitoring of the patient’s condition, including endoscopy, laboratory tests of blood and stool. Strepsils Intensive is not recommended to be combined with the consumption of ethanol-containing products. Due to the risk of deterioration in the functional characteristics of the kidneys, persons suffering from insufficiency of kidney and liver function, as well as those who are elderly, should consult a doctor before using the drug. The drug is not recommended to be combined with other NSAIDs to avoid increasing the risk of side effects. Caution is required when combining Strepsils Intensive with anticoagulants.